Literature DB >> 16877656

Poverty and response to treatment among panic disorder patients in primary care.

Peter Roy-Byrne1, Cathy Sherbourne, Jeanne Miranda, Murray Stein, Michelle Craske, Daniela Golinelli, Greer Sullivan.   

Abstract

OBJECTIVE: Despite well-established links between poverty and poor mental illness outcome as well as recent reports exploring racial and ethnic health disparities, little is known about the outcomes of evidence-based psychiatric treatment for poor individuals.
METHOD: Primary care patients with panic disorder (N=232) who were participating in a randomized controlled trial comparing a cognitive behavior therapy (CBT) and pharmacotherapy intervention to usual care were divided into those patients above (N=152) and below (N=80) the poverty line. Telephone assessments at 3, 6, 9, and 12 months were used to compare the amount of evidence-based care received as well as clinical and functional outcomes.
RESULTS: Poor subjects were more severely ill at baseline, with more medical and psychiatric comorbidity. The increases in the amount of evidence-based care and reductions in clinical symptoms and disability were comparable in the two groups such that poorer individuals, although responding equivalently, continued to be more ill and disabled at 12 months.
CONCLUSIONS: The comparable response of poor individuals in this study suggests that standard CBT and pharmacotherapy treatments for panic disorder do not need to be "tailored" to be effective in poor populations. However, the more severe illness both at baseline and follow-up in these poor individuals suggests that treatment programs may need to be extended in order to treat residual symptoms and disability in these patients so that they might achieve comparable levels of remission.

Entities:  

Mesh:

Year:  2006        PMID: 16877656     DOI: 10.1176/ajp.2006.163.8.1419

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  7 in total

1.  Trajectories of change in anxiety severity and impairment during and after treatment with evidence-based treatment for multiple anxiety disorders in primary care.

Authors:  Jutta M Joesch; Daniela Golinelli; Cathy D Sherbourne; Greer Sullivan; Murray B Stein; Michelle G Craske; Peter P Roy-Byrne
Journal:  Depress Anxiety       Date:  2013-06-25       Impact factor: 6.505

2.  The Interplay of Familial and Individual Risk in Predicting Clinical Improvements in Pediatric Anxiety Disorders.

Authors:  Cara J Kiff; Stephanie Ernestus; Araceli Gonzalez; Philip C Kendall; Anne Marie Albano; Scott N Compton; Boris Birmaher; Golda S Ginsburg; Moira Rynn; John T Walkup; James McCracken; John Piacentini
Journal:  J Clin Child Adolesc Psychol       Date:  2018-06-07

3.  Collaborative depression care: history, evolution and ways to enhance dissemination and sustainability.

Authors:  Wayne Katon; Jürgen Unützer; Kenneth Wells; Loretta Jones
Journal:  Gen Hosp Psychiatry       Date:  2010-05-07       Impact factor: 3.238

4.  Does a quality improvement intervention for anxiety result in differential outcomes for lower-income patients?

Authors:  Greer Sullivan; Cathy Sherbourne; Denise A Chavira; Michelle G Craske; Daniela Gollineli; Xiaotong Han; Raphael D Rose; Alexander Bystritsky; Murray B Stein; Peter Roy-Byrne
Journal:  Am J Psychiatry       Date:  2013-02       Impact factor: 18.112

5.  Clinical presentation and treatment outcome of African Americans with complicated grief.

Authors:  Mario Cruz; John Scott; Patricia Houck; Charles F Reynolds; Ellen Frank; M Katherine Shear
Journal:  Psychiatr Serv       Date:  2007-05       Impact factor: 3.084

6.  Effect of dissociative experiences on drug treatment of panic disorder.

Authors:  Murat Gulsun; Ali Doruk; Ozcan Uzun; Tümer Turkbay; Aytekin Ozsahin
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

7.  Socioeconomic status and the effectiveness of treatment for first-episode psychosis.

Authors:  Daniel Bennett; Robert Rosenheck
Journal:  Health Serv Res       Date:  2020-11-24       Impact factor: 3.734

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.